

PRESS RELEASE

Gradientech distributor Iberlab wins significant tender for QuickMIC® in Portugal

Uppsala, Sweden, January 12, 2026. The diagnostics company Gradientech, together with its Portuguese distributor Iberlab, today announces the successful award of a direct tender for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) directly from positive blood culture samples.

The Portuguese Hospital Unidade Local de Saúde da Guarda (ULS Guarda) has, following a direct tender procedure, selected QuickMIC® for integration into their clinical workflow for AST of sepsis samples. ULS Guarda is the principal public hospital serving the Guarda district and surrounding areas, delivering comprehensive acute and specialised healthcare.

This award underscores the growing clinical adoption of QuickMIC® for routine use and further strengthens Gradientech's commercial footprint in Southern Europe.

"This tender win is a strong endorsement of the QuickMIC® system and its ability to deliver ultra-rapid, actionable antimicrobial susceptibility results to Portuguese hospitals," comments João Teixeira, CEO of Iberlab at Iberlab. "We're proud to support clinicians with a solution that can make a real difference in patient care and look forward to expanding access to QuickMIC® across Portugal."

"We are pleased to see QuickMIC® selected in this competitive tender," says Sara Thorslund, CEO and co-founder of Gradientech. "This reflects growing recognition of QuickMIC® as a valuable tool for faster, informed antibiotic decisions and reinforces the trust healthcare systems place in our technology — and in Iberlab as a strong local partner."

QuickMIC® and its Gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO

Tel: +46 736 29 35 80

sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.